Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons

Krishna C. Vadodaria, Yuan Ji, Michelle Skime, Apua C. Paquola, Timothy J Nelson, Daniel Hall-Flavin, Kelly J. Heard, Callie Fredlender, Yalin Deng, James Elkins, Komal Dani, Amy T. Le, Maria C. Marchetto, Richard M Weinshilboum, Fred H. Gage

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Disrupted serotonergic neurotransmission has long been implicated in major depressive disorder (MDD), for which selective serotonin reuptake inhibitors (SSRIs) are the first line of treatment. However, a significant percentage of patients remain SSRI-resistant and it is unclear whether and how alterations in serotonergic neurons contribute to SSRI resistance in these patients. Induced pluripotent stem cells (iPSCs) facilitate the study of patient-specific neural subtypes that are typically inaccessible in living patients, enabling the discovery of disease-related phenotypes. In our study of a well-characterized cohort of over 800 MDD patients, we generated iPSCs and serotonergic neurons from three extreme SSRI-remitters (R) and SSRI-nonremitters (NR). We studied serotonin (5-HT) biochemistry and observed no significant differences in 5-HT release and reuptake or in genes related to 5-HT biochemistry. NR patient-derived serotonergic neurons exhibited altered neurite growth and morphology downstream of lowered expression of key Protocadherin alpha genes as compared to healthy controls and Rs. Furthermore, knockdown of Protocadherin alpha genes directly regulated iPSC-derived neurite length and morphology. Our results suggest that intrinsic differences in serotonergic neuron morphology and the resulting circuitry may contribute to SSRI resistance in MDD patients.

Original languageEnglish (US)
JournalMolecular Psychiatry
DOIs
StatePublished - Jan 1 2019

Fingerprint

Major Depressive Disorder
Serotonin Uptake Inhibitors
Serotonergic Neurons
Neurons
Induced Pluripotent Stem Cells
Serotonin
Neurites
Biochemistry
Genes
Synaptic Transmission
Phenotype
Growth

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons. / Vadodaria, Krishna C.; Ji, Yuan; Skime, Michelle; Paquola, Apua C.; Nelson, Timothy J; Hall-Flavin, Daniel; Heard, Kelly J.; Fredlender, Callie; Deng, Yalin; Elkins, James; Dani, Komal; Le, Amy T.; Marchetto, Maria C.; Weinshilboum, Richard M; Gage, Fred H.

In: Molecular Psychiatry, 01.01.2019.

Research output: Contribution to journalArticle

Vadodaria, KC, Ji, Y, Skime, M, Paquola, AC, Nelson, TJ, Hall-Flavin, D, Heard, KJ, Fredlender, C, Deng, Y, Elkins, J, Dani, K, Le, AT, Marchetto, MC, Weinshilboum, RM & Gage, FH 2019, 'Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons', Molecular Psychiatry. https://doi.org/10.1038/s41380-019-0377-5
Vadodaria, Krishna C. ; Ji, Yuan ; Skime, Michelle ; Paquola, Apua C. ; Nelson, Timothy J ; Hall-Flavin, Daniel ; Heard, Kelly J. ; Fredlender, Callie ; Deng, Yalin ; Elkins, James ; Dani, Komal ; Le, Amy T. ; Marchetto, Maria C. ; Weinshilboum, Richard M ; Gage, Fred H. / Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons. In: Molecular Psychiatry. 2019.
@article{1f202b93ac984e6399cb89eff5224279,
title = "Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons",
abstract = "Disrupted serotonergic neurotransmission has long been implicated in major depressive disorder (MDD), for which selective serotonin reuptake inhibitors (SSRIs) are the first line of treatment. However, a significant percentage of patients remain SSRI-resistant and it is unclear whether and how alterations in serotonergic neurons contribute to SSRI resistance in these patients. Induced pluripotent stem cells (iPSCs) facilitate the study of patient-specific neural subtypes that are typically inaccessible in living patients, enabling the discovery of disease-related phenotypes. In our study of a well-characterized cohort of over 800 MDD patients, we generated iPSCs and serotonergic neurons from three extreme SSRI-remitters (R) and SSRI-nonremitters (NR). We studied serotonin (5-HT) biochemistry and observed no significant differences in 5-HT release and reuptake or in genes related to 5-HT biochemistry. NR patient-derived serotonergic neurons exhibited altered neurite growth and morphology downstream of lowered expression of key Protocadherin alpha genes as compared to healthy controls and Rs. Furthermore, knockdown of Protocadherin alpha genes directly regulated iPSC-derived neurite length and morphology. Our results suggest that intrinsic differences in serotonergic neuron morphology and the resulting circuitry may contribute to SSRI resistance in MDD patients.",
author = "Vadodaria, {Krishna C.} and Yuan Ji and Michelle Skime and Paquola, {Apua C.} and Nelson, {Timothy J} and Daniel Hall-Flavin and Heard, {Kelly J.} and Callie Fredlender and Yalin Deng and James Elkins and Komal Dani and Le, {Amy T.} and Marchetto, {Maria C.} and Weinshilboum, {Richard M} and Gage, {Fred H.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41380-019-0377-5",
language = "English (US)",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons

AU - Vadodaria, Krishna C.

AU - Ji, Yuan

AU - Skime, Michelle

AU - Paquola, Apua C.

AU - Nelson, Timothy J

AU - Hall-Flavin, Daniel

AU - Heard, Kelly J.

AU - Fredlender, Callie

AU - Deng, Yalin

AU - Elkins, James

AU - Dani, Komal

AU - Le, Amy T.

AU - Marchetto, Maria C.

AU - Weinshilboum, Richard M

AU - Gage, Fred H.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Disrupted serotonergic neurotransmission has long been implicated in major depressive disorder (MDD), for which selective serotonin reuptake inhibitors (SSRIs) are the first line of treatment. However, a significant percentage of patients remain SSRI-resistant and it is unclear whether and how alterations in serotonergic neurons contribute to SSRI resistance in these patients. Induced pluripotent stem cells (iPSCs) facilitate the study of patient-specific neural subtypes that are typically inaccessible in living patients, enabling the discovery of disease-related phenotypes. In our study of a well-characterized cohort of over 800 MDD patients, we generated iPSCs and serotonergic neurons from three extreme SSRI-remitters (R) and SSRI-nonremitters (NR). We studied serotonin (5-HT) biochemistry and observed no significant differences in 5-HT release and reuptake or in genes related to 5-HT biochemistry. NR patient-derived serotonergic neurons exhibited altered neurite growth and morphology downstream of lowered expression of key Protocadherin alpha genes as compared to healthy controls and Rs. Furthermore, knockdown of Protocadherin alpha genes directly regulated iPSC-derived neurite length and morphology. Our results suggest that intrinsic differences in serotonergic neuron morphology and the resulting circuitry may contribute to SSRI resistance in MDD patients.

AB - Disrupted serotonergic neurotransmission has long been implicated in major depressive disorder (MDD), for which selective serotonin reuptake inhibitors (SSRIs) are the first line of treatment. However, a significant percentage of patients remain SSRI-resistant and it is unclear whether and how alterations in serotonergic neurons contribute to SSRI resistance in these patients. Induced pluripotent stem cells (iPSCs) facilitate the study of patient-specific neural subtypes that are typically inaccessible in living patients, enabling the discovery of disease-related phenotypes. In our study of a well-characterized cohort of over 800 MDD patients, we generated iPSCs and serotonergic neurons from three extreme SSRI-remitters (R) and SSRI-nonremitters (NR). We studied serotonin (5-HT) biochemistry and observed no significant differences in 5-HT release and reuptake or in genes related to 5-HT biochemistry. NR patient-derived serotonergic neurons exhibited altered neurite growth and morphology downstream of lowered expression of key Protocadherin alpha genes as compared to healthy controls and Rs. Furthermore, knockdown of Protocadherin alpha genes directly regulated iPSC-derived neurite length and morphology. Our results suggest that intrinsic differences in serotonergic neuron morphology and the resulting circuitry may contribute to SSRI resistance in MDD patients.

UR - http://www.scopus.com/inward/record.url?scp=85063390126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063390126&partnerID=8YFLogxK

U2 - 10.1038/s41380-019-0377-5

DO - 10.1038/s41380-019-0377-5

M3 - Article

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

ER -